Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date26 Sep 2020 |
100 Clinical Results associated with Yunnan Datang Hanfang Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Yunnan Datang Hanfang Pharmaceutical Co., Ltd.
100 Deals associated with Yunnan Datang Hanfang Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Yunnan Datang Hanfang Pharmaceutical Co., Ltd.